Clinical Trial Update: A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition [Phase 2]

View source ↗

Summary

Phase 2 clinical trial sponsored by Regeneron evaluating a gene-silencing therapy for Metabolic Dysfunction-associated Steatohepatitis (MASH) in adults at incre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatohepatitis

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Status: RECRUITING